Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Whitehawk Therapeutics Inc's Business Segments
Whitehawk Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Reportable Segment
Total Revenue
$ 7
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Reportable Segment100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable Segment | $ 7 | 100% |
Revenue by Product & Service Category - Q1 FY2025
- Product100%
Revenue by Product & Service Category - Q1 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 7 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Whitehawk Therapeutics Inc
The company is a clinical-stage oncology therapeutics firm specializing in developing cancer treatments by applying advanced technologies to established tumor biology. It possesses expertise in chemistry, formulation, drug delivery, and pharmaceutical development, with experience advancing product candidates from clinical trials to commercialization. In December 2024, the company licensed a portfolio of three next-generation antibody drug conjugates (ADCs) from WuXi Biologics and Hangzhou DAC Biotechnology. These ADCs target tumor antigens PTK7, MUC16, and SEZ6, utilizing a CPT113 linker-payload platform that delivers a Topoisomerase I inhibitor directly to cancer cells. The company has submitted and received FDA clearance for investigational new drug applications for HWK-007 and HWK-016, with Phase 1 trials actively recruiting and data expected in early 2027. An IND for HWK-206 is anticipated in mid-2026. Previously, the company developed FYARRO®, a nanoparticle albumin-bound sirolimus product for advanced malignant PEComa, which it divested in March 2025. Its strategy focuses on next-generation ADC architectures, clinically validated targets, innovative antibody design, differentiation from first-generation ADCs, and an efficient virtual model with outsourced clinical development and manufacturing, including ongoing collaboration with WuXi Biologics.
The Company operates a single reportable segment focused on applying advanced technologies to established tumor biology to develop cancer treatments. The Chief Executive Officer serves as the chief operating decision maker, evaluating performance based on research and development expenses and net income or loss. Segment revenues were derived from sales of FYARRO, which was divested on March 25, 2025. All segment assets and operations are based in the United States. Major segment expenses include research and development, contract manufacturing, commercial and marketing, finance and accounting, legal, selling, general and administrative expenses, cost of sales, interest expense, other income, foreign exchange loss, and gain on sale of business. The Company divested FYARRO by selling 100% of the outstanding shares of Aadi Subsidiary to KAKEN PHARMACEUTICAL CO., LTD, receiving $102.4 million in cash and recording a net gain of $87.3 million on the sale at closing on March 25, 2025.